Effects of voriconazole on Candida glabratain vitro

Nguyen, M. H., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R. et al. (1996). The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. American Journal of Medicine100, 617– 23.

Belanger, P., Nast, C. C., Fratti, R., Sanati, H. & Ghannoum, M. (1997). Voriconazole (UK-109, 496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrobial Agents and Chemotherapy41, 1840–2.

Hitchcock, C. A., Pye, L. W., Oliver, G. P. & Troke, P. F. (1995). UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F72, p. 125. American Society for Microbiology, Washington, DC.

National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA.

Sanati, H., Belanger, P., Fratti, R. & Ghannoum, M. (1997). A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei.Antimicrobial Agents and Chemotherapy41, 2492–6.

Koul, A., Chandra, J. C. & Prasad, R. (1995). Status of membrane lipids and amino acid transport in morphological mutants of Candida albicans.Biochemistry and Molecular Biology International35, 1215–22.

Ghannoum, M. A., Abu Elteen, K., Ellabib, M. & Whittaker, P. A. (1990). Antimycotic effects of octenidine and pirtenidine. Journal of Antimicrobial Chemotherapy25, 237–45.

Hitchcock, C. A. & Whittle, P. J. (1993). Chemistry and mode of action of fluconazole. In Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development (Ripen, J. W. & Fromtling, R. A., Eds), pp. 183–97. Marcel Dekker, New York, NY.